Case Report

Perinuclear antineutrophil cytoplasmic antibody–associated vasculitis in an elderly woman

Tina Hu MSc  Neil D. Dattani MD  Christian Pagnoux MD MPH  Rahul Jain MD CCFP

EDITOR’S KEY POINTS

• A multisystem disease process not caused by infection or malignancy should raise concern about small-vessel vasculitis. Palpable purpura (raised and nonblanching) in the lower extremities is the most common and suggestive skin manifestation, and much less specific constitutional symptoms, such as fever, fatigue, arthritis, and renal and pulmonary involvement, are also common.

• Although not present in every patient, the presence of perinuclear antineutrophil cytoplasmic antibody (ANCA) or cytoplasmic ANCA can help distinguish among ANCA-associated small-vessel vasculitis subtypes (ie, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, and microscopic polyangiitis).

• For patients with organ-threatening disease, treatment with glucocorticoids combined with cyclophosphamide or rituximab is recommended for inducing remission. Once remission is achieved after 3 to 6 months of induction therapy, maintenance therapy must be given for a minimum of 18 to 24 months, most often with azathioprine or methotrexate; the glucocorticoid dosage is tapered during this time.

ANTINEUTROPHIL CYTOPLASMIC ANTIBODY

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis encompasses 3 conditions: eosinophilic granulomatosis with polyangiitis (EGPA; formerly named Churg-Strauss syndrome), granulomatosis with polyangiitis (GPA; formerly named Wegener granulomatosis), and microscopic polyangiitis.1 Diagnosing ANCA-associated small-vessel vasculitis is challenging for clinicians because of its infrequent presentation (incidence of 20 per 1 million) and variable clinical manifestations.1,2 Antineutrophil cytoplasmic antibody–associated small-vessel vasculitis generally presents as a multisystem disease.2 Here we describe a case of ANCA-associated small-vessel vasculitis that underlines why it is important for family physicians to be familiar with this condition and to have an appropriately high index of suspicion to prevent life-threatening end-organ damage.3

Case

An 87-year-old non-smoking woman presented to the emergency department after experiencing multiple non-specific symptoms during the previous 2 months including fevers, weight loss, generalized arthralgia, headaches, chronic nonproductive cough, and progressive proximal leg weakness. Her past medical history was relevant for hypertension, type 2 diabetes, asthma, and bilateral lung nodules. She reported no sick contacts or recent travel outside of Canada.

Physical examination findings were unremarkable except for a fever of 38.3°C and bilateral proximal lower extremity weakness. A complete blood count revealed microcytic anemia (hemoglobin level of 93 g/L and a mean corpuscular volume of 77 fl), neutrophilia (neutrophil count of 18.6×10^9/L), a normal eosinophil count (0.2×10^9/L), an elevated erythrocyte sedimentation

This article has been peer reviewed.

Cet article a fait l’objet d’une révision par des pairs.

Can Fam Physician 2016;62:635-7
Vasculitis is inflammation of blood vessel walls and it may be triggered by an infection or caused by an inflammatory process such as a vasculitis rash (raised and nonblanching) in the lower extremities is the most common and suggestive skin manifestation.3 Much less specific constitutional symptoms, such as fever, fatigue, arthritis, and renal and pulmonary involvement, are also common manifestations of small-vessel vasculitis.2 Vasculitis affects vessels smaller than arteries (ie, arterioles, capillaries, and venules).1 Small-vessel vasculitis affects vessels smaller than arteries (ie, arterioles, capillaries, and venules).1

Family physicians should be aware of the potential clinical manifestations of small-vessel vasculitis, which are shown in Table 1.1,3 A multisystem disease process not caused by infection or malignancy should raise concern about small-vessel vasculitis.3 Palpable purpura (raised and nonblanching) in the lower extremities is the most common and suggestive skin manifestation.3 Much less specific constitutional symptoms, such as fever, fatigue, arthritis, and renal and pulmonary involvement, are also common manifestations of small-vessel vasculitis, sometimes occurring in isolation for several weeks at disease onset.2,3 It is important to differentiate small-vessel vasculitis from other conditions that can cause multisystem symptoms. The differential diagnosis includes ant–glomerular basement membrane antibody disease, antiphospholipid syndrome, cocaine use, hypersensitivity reactions, multiple myeloma, paraneoplastic syndromes, and secondary causes of vasculitis (ie, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, cancer, and hepatitis B and C infections).3 Typical laboratory findings for vasculitis are anemia, leukocytosis, elevated inflammatory markers, and renal findings with abnormal urinalysis results.3

To help determine the type of small-vessel vasculitis, testing for ANCA should be completed.2,3 Antineutrophil cytoplasmic antibodies work against neutrophil antigens and show 2 important staining patterns: c-ANCA, mainly seen with antibodies to proteinase 3 on ELISA, and p-ANCA, mainly seen with antibodies to myeloperoxidase on ELISA.2 Although not present in every patient, the presence of p-ANCA or c-ANCA can help further distinguish among ANCA-associated small-vessel vasculitis subtypes.2 As previously discussed, ANCA-associated small-vessel vasculitis can be subdivided into EGPA, GPA, and microscopic polyangiitis.1 Test results for c-ANCA are positive in 75% to 90% of GPA cases, while the presence of p-ANCA is more characteristic of microscopic polyangiitis and EGPA.2,3 Table 2 shows clinical features of ANCA-associated small-vessel vasculitis.1,3

Treatment involves 2 phases: induction and maintenance.3 For patients with organ-threatening disease, treatment with glucocorticoids combined with cyclophosphamide or rituximab is recommended for inducing remission.3,4 The patient in the presented case did not receive cyclophosphamide or rituximab because her condition was clinically much improved by the time she presented to the vasculitis clinic. However, glucocorticoids

**Table 1. Most common clinical manifestations of small-vessel vasculitis**

<table>
<thead>
<tr>
<th>SYSTEM</th>
<th>CLINICAL MANIFESTATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constitutional</td>
<td>Fatigue, fever (&gt;38°C), weight loss (&gt;2 kg), night sweats</td>
</tr>
<tr>
<td>Ear, nose, and throat</td>
<td>Bloody nasal discharge, subglottic stenosis, ulcers</td>
</tr>
<tr>
<td>Gastrointestinal tract</td>
<td>Abdominal pain, bloody diarrhea</td>
</tr>
<tr>
<td>Kidneys</td>
<td>Hypertension, proteinuria, microscopic hematuria, renal insufficiency, necrotizing glomerulonephritis, renal failure</td>
</tr>
<tr>
<td>Musculoskeletal system</td>
<td>Arthralgia, myalgia</td>
</tr>
<tr>
<td>Nervous system</td>
<td>Neuropathy (mononeuropathy multiplex), headache</td>
</tr>
<tr>
<td>Respiratory tract</td>
<td>Dyspnea, cough, asthma (EGPA), hemoptysis, alveolar hemorrhage, lung infiltrates, lung nodules, pleural effusions</td>
</tr>
<tr>
<td>Skin</td>
<td>Palpable purpura, urticarial rash</td>
</tr>
</tbody>
</table>

EGPA—eosinophilic granulomatosis with polyangiitis. Adapted from Jennette et al,1 Jennette and Falk,2 and Sharma et al.3
alone are generally not sufficient and cyclophosphamide or rituximab are needed to induce remission. Glucocorticoids are given orally (1 mg/kg/d, up to 60 mg/d), possibly preceded by pulsed intravenous doses of methylprednisolone (7.5 to 15 mg/kg/d) for the first 3 days, with oral cyclophosphamide (1 to 2 mg/kg/d, up to 200 mg/d, adjusted for renal function and patient age) or intravenous pulsed cyclophosphamide (7.5 to 15 mg/kg per pulse, on days 1, 15, and 29, and then every 3 weeks). Rituximab can be used if these standard treatments fail or in case of contraindications to cyclophosphamide use. For patients with life-threatening disease (eg, pulmonary hemorrhage, severe renal failure), additional treatment with plasma exchange can be considered. Once remission is achieved after 3 to 6 months of induction therapy, maintenance therapy must be given for a minimum of 18 to 24 months, most often with azathioprine or methotrexate (repeat low-dose rituximab infusions might become another maintenance option in the future); the glucocorticoid dosage is tapered during this time. As all these treatments are immunosuppressive, family physicians should closely monitor patients for potential complications, such as infections and hemorrhagic cystitis, in collaboration with centres that specialize in vasculitis such as those listed at www.canvasc.ca.

### Conclusion

As family physicians are frequently the first point of contact for patients with ANCA-associated small-vessel vasculitis, it is important to be aware of the common clinical manifestations of this condition, which can lead to life-threatening organ failure if not diagnosed and treated promptly. In caring for these complex patients, family physicians often collaborate with various other specialists.

**Ms Hu** is a medical student at the University of Toronto in Ontario. **Dr Dattani** is a second-year family medicine resident at the University of Toronto. **Dr Pagnoux** is a rheumatologist at the Vasculitis Clinic at Mount Sinai Hospital in Toronto. **Dr Jain** is a family physician at Sunnybrook Health Sciences Centre in Toronto.

**Competing interests**

None declared

**Correspondence**

Ms Tina Hu, e-mail tina.hu@mail.utoronto.ca

**References**